TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity in Women With Infants
Brief Summary: This is a study testing ways to motivate new mothers to become more physically active over a one year period.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Exercise and education; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): 2
B: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
C: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity in Women With Infants
Brief Summary: This is a study testing ways to motivate new mothers to become more physically active over a one year period.


Options:
A: Arm Label: 10,000 step/day recommendation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 10,000 step/day recommendation | Arm Label: Adaptive recommendation; Type: EXPERIMENTAL; Interventions: Behavioral: Adaptive step recommendation | Intervention Type: BEHAVIORAL; Name: Adaptive step recommendation; Assigned to Arm(s): Adaptive recommendation | Intervention Type: BEHAVIORAL; Name: 10,000 step/day recommendation; Assigned to Arm(s): 10,000 step/day recommendation
B: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
C: Arm Label: Facebook and Text Message; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook and text Message | Arm Label: Standard Print-based Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Print-based Intervention | Intervention Type: BEHAVIORAL; Name: Facebook and text Message; Assigned to Arm(s): Facebook and Text Message | Intervention Type: BEHAVIORAL; Name: Standard Print-based Intervention; Assigned to Arm(s): Standard Print-based Intervention
D: Arm Label: High reinforcement cessation program; Type: EXPERIMENTAL; Interventions: Behavioral: high reinforcement cessation program | Arm Label: Low reinforcement cessation program; Type: EXPERIMENTAL; Interventions: Behavioral: low reinforcement cessation program | Intervention Type: BEHAVIORAL; Name: high reinforcement cessation program; Assigned to Arm(s): High reinforcement cessation program | Intervention Type: BEHAVIORAL; Name: low reinforcement cessation program; Assigned to Arm(s): Low reinforcement cessation program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity in Women With Infants
Brief Summary: This is a study testing ways to motivate new mothers to become more physically active over a one year period.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Phone counseling with written materials | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Phone counseling with written materials; Assigned to Arm(s): Intervention Group
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mini Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Mini Booster | Arm Label: Full Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Full Booster | Intervention Type: BEHAVIORAL; Name: Mini Booster; Assigned to Arm(s): Mini Booster | Intervention Type: BEHAVIORAL; Name: Full Booster; Assigned to Arm(s): Full Booster
C: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
D: Intervention Type: BEHAVIORAL; Name: Physical activity (PA) and immigrants; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity in Women With Infants
Brief Summary: This is a study testing ways to motivate new mothers to become more physically active over a one year period.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mini Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Mini Booster | Arm Label: Full Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Full Booster | Intervention Type: BEHAVIORAL; Name: Mini Booster; Assigned to Arm(s): Mini Booster | Intervention Type: BEHAVIORAL; Name: Full Booster; Assigned to Arm(s): Full Booster
B: Arm Label: PA intervention and Maintenance plus; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance plus | Arm Label: PA intervention and Maintenance regular; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance regular | Arm Label: Pedometer; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control (pedometer only) | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance plus; Assigned to Arm(s): PA intervention and Maintenance plus | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance regular; Assigned to Arm(s): PA intervention and Maintenance regular | Intervention Type: BEHAVIORAL; Name: Control (pedometer only); Assigned to Arm(s): Pedometer
C: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
D: Arm Label: Tailored Physical Activity Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Physical Activity Intervention | Arm Label: No Tailored Physical Activity Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored Physical Activity Intervention; Assigned to Arm(s): Tailored Physical Activity Intervention Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Brief Summary: The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1
B: Arm Label: Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Spot Sign for Predicting and Treating Intracerebral Hemorrhage Growth Study
Brief Summary: The purpose of this study is to determine if computed tomography angiography can predict which individuals with intracerebral hemorrhage will experience significant growth in the size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study will compare the drug recombinant activated factor VII (rFVIIa) to placebo to determine the effect of rFVIIa on intracerebral hemorrhage growth.


Options:
A: Arm Label: Group 1-Recombinant activated factor VII; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant activated factor VII | Arm Label: Group 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Group 3 - Observation Only Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: recombinant activated factor VII; Assigned to Arm(s): Group 1-Recombinant activated factor VII | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group 2 - Placebo
B: Arm Label: Niastase RT; Type: ACTIVE_COMPARATOR; Interventions: Biological: rfVIIa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard saline solution | Intervention Type: BIOLOGICAL; Name: rfVIIa; Assigned to Arm(s): Niastase RT | Intervention Type: OTHER; Name: Standard saline solution; Assigned to Arm(s): Placebo
C: Arm Label: Tranexamic Acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Drug: Desmopressin Injection | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Desmopressin Injection; Assigned to Arm(s): Intervention | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tocolysis for Preterm Labor
Brief Summary: Preterm birth is the most common and costly complication in obstetrics. It complicates up to 11% of all pregnancies and it is responsible for 70% of sick babies. The ideal way to stop preterm labor when it occurs (which drug to use) is not known. Currently magnesium sulfate is used by about 95% of all practitioners, but recent data suggest magnesium given this way may be harmful for the baby's future development. Other drugs such as antiprostaglandin agents are very effective in stopping uterine activity, but particularly when used for \>48 hours have been associated with both maternal and fetal sides effects. Lastly, calcium channel antagonists are effective in stopping contractions and have very little in the way of maternal and fetal side effects, but less data is available in the United States on their use. Because there is no FDA approved drug to stop preterm labor, we purpose to randomize all women with preterm labor (20-34 weeks) to receive one of the above three methods of stopping preterm labor. The primary outcomes will be to see which agent stops the uterine contractions most effectively, for the longest period of time with fewest relapses and results in significant prolongation of pregnancy. If one of these agents is clearly superior to the other two it would help women avoid early delivery or have significant extension of their pregnancy to avoid some of the complications of preterm birth in the baby.


Options:
A: Arm Label: Utrogestan; Type: ACTIVE_COMPARATOR; Interventions: Drug: utrogestan | Arm Label: Nifedipine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: utrogestan; Assigned to Arm(s): Utrogestan | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
B: Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Arm Label: Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin
C: Arm Label: 1 Magnesium Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1 Magnesium Sulfate | Arm Label: 2 Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Arm Label: 3 Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Intervention Type: DRUG; Name: 1 Magnesium Sulfate; Assigned to Arm(s): 1 Magnesium Sulfate | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): 2 Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): 3 Indomethacin
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HEMOTOL: Effects of New Dialysis On-line Monitoring Devices on Hemodynamic Stability During Intermittent Hemodialysis in Critically Ill Patients With Acute Kidney Injury : a Prospective Randomized Study.
Brief Summary: The purpose of this randomized controlled study is to compare the effects of different new dialysis on-line monitoring devices on hemodynamic stability during intermittent hemodialysis in critically ill patients with acute kidney injury.


Options:
A: Arm Label: Subjects undergoing sodium alignment; Type: N/A; Interventions: Other: Dialysate and serum sodium concentration aligned | Arm Label: Subjects not undergoing sodium alignment; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: Dialysate and serum sodium concentration aligned; Assigned to Arm(s): Subjects undergoing sodium alignment
B: Arm Label: Conventional hemodialysis; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional hemodialysis | Arm Label: Frequent hemodialysis; Type: EXPERIMENTAL; Interventions: Device: Frequent hemodialysis | Intervention Type: DEVICE; Name: Conventional hemodialysis; Assigned to Arm(s): Conventional hemodialysis | Intervention Type: DEVICE; Name: Frequent hemodialysis; Assigned to Arm(s): Frequent hemodialysis
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nocturnal home hemodialysis | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nocturnal home hemodialysis | Intervention Type: BEHAVIORAL; Name: Nocturnal home hemodialysis; Assigned to Arm(s): 1, 2
D: Arm Label: Standard; Type: NO_INTERVENTION; Interventions: Device: Standard Hemodialysis | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: with Blood Volume Management (BVM®) only | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring | Intervention Type: DEVICE; Name: Standard Hemodialysis; Assigned to Arm(s): Standard | Intervention Type: DEVICE; Name: with Blood Volume Management (BVM®) only; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed Dose Study Comparing the Efficacy and Safety of [Vortioxetine] Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients
Brief Summary: To assess the efficacy of Vortioxetine (5 mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale (HAM-D24) total score after 8 weeks of double-blind treatment in elderly patients.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 10 mg, Vortioxetine 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Duloxetine 60 mg; Type: OTHER; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 5 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Duloxetine 60 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 15 mg, Vortioxetine 20 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine (Lu AA21004) 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine (Lu AA21004) 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Venlafaxine XL 225 mg; Type: OTHER; Interventions: Drug: Venlafaxine XL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine (Lu AA21004) 10 mg, Vortioxetine (Lu AA21004) 5 mg | Intervention Type: DRUG; Name: Venlafaxine XL; Assigned to Arm(s): Venlafaxine XL 225 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed Dose Study Comparing the Efficacy and Safety of [Vortioxetine] Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients
Brief Summary: To assess the efficacy of Vortioxetine (5 mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale (HAM-D24) total score after 8 weeks of double-blind treatment in elderly patients.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Duloxetine 60 mg; Type: OTHER; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 5 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg
B: Intervention Type: DRUG; Name: Quetiapine fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine 60mg; Type: OTHER; Interventions: Drug: Duloxetine 60 mg/day | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg/day; Assigned to Arm(s): Duloxetine 60mg

Answer: A